Clarke S E, Baldwin S J, Bloomer J C, Ayrton A D, Sozio R S, Chenery R J
Department of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, Welwyn, Herts, U.K.
Chem Res Toxicol. 1994 Nov-Dec;7(6):836-42. doi: 10.1021/tx00042a018.
In vitro techniques have been utilized to investigate the microsomal enzymes involved in the metabolism of lauric acid and to establish conditions in which it can be used as a model substrate for both cytochrome P450 4A and cytochrome P450 2E1 in human liver microsomes. Studies of enzyme kinetics of lauric acid omega-hydroxylation in human liver microsomes indicated the involvement of more than one enzyme in this pathway, a relatively low Km enzyme with a Km of 22 microM +/- 12 (n = 8) and a high Km enzyme with a Km an order of magnitude higher (550 microM +/- 310, n = 7). The apparent Vmax for this component correlated with the rate of cyclosporin metabolism and was highly sensitive to ketoconazole inhibition. These results indicated that this enzyme was a member of the 3A subfamily. The activity associated with the low Km enzyme (P450 4A) did not correlate with P450 1A2, 2A6, 2C9/8, 2C19, 2D6, 2E1, or 3A activities in a bank of human liver microsomes and was not appreciably inhibited by ketoconazole, furafylline, quinidine, sulfaphenazole, or diethyldithiocarbamate (DDC). Lauric acid omega-1 hydroxylation demonstrated simple Michaelis-Menten kinetics in each of the human liver microsomal samples examined, with a Km of 130 microM +/- 42 (n = 8). This activity was highly correlated with chlorzoxazone 6-hydroxylation in human liver microsomes (r = 0.98, n = 14, p < 0.001) and was inhibited by both DDC and chlorzoxazone. Additionally, rats treated with the P450 2E1 inducer isoniazid demonstrated a 3-fold increase in lauric acid omega-1 hydroxylation relative to the control group. Thus, the lauric acid hydroxylation assay, at a substrate concentration of 20 microM, appears to be an effective and specific P450 model substrate capable of determining simultaneously P450 4A and P450 2E1 related activities in hepatic microsomal samples.
已利用体外技术研究参与月桂酸代谢的微粒体酶,并确定其可作为人肝微粒体中细胞色素P450 4A和细胞色素P450 2E1的模型底物的条件。对人肝微粒体中月桂酸ω-羟化的酶动力学研究表明,该途径涉及不止一种酶,一种Km相对较低的酶,Km为22 μM±12(n = 8),以及一种Km高一个数量级的高Km酶(550 μM±310,n = 7)。该组分的表观Vmax与环孢素代谢速率相关,且对酮康唑抑制高度敏感。这些结果表明该酶是3A亚家族的成员。与低Km酶(P450 4A)相关的活性与一组人肝微粒体中的P450 1A2、2A6、2C9/8、2C19、2D6、2E1或3A活性无关,且未被酮康唑、呋拉茶碱、奎尼丁、磺胺苯吡唑或二乙基二硫代氨基甲酸盐(DDC)明显抑制。在所检测的每个人肝微粒体样品中,月桂酸ω-1羟化均表现出简单的米氏动力学,Km为130 μM±42(n = 8)。该活性与人肝微粒体中氯唑沙宗6-羟化高度相关(r = 0.98,n = 14, p < 0.001),且被DDC和氯唑沙宗抑制。此外,用细胞色素P450 2E1诱导剂异烟肼处理的大鼠,其月桂酸ω-1羟化相对于对照组增加了3倍。因此,在底物浓度为20 μM时,月桂酸羟化测定似乎是一种有效且特异的细胞色素P450模型底物,能够同时测定肝微粒体样品中与细胞色素P450 4A和细胞色素P450 2E1相关的活性。